---
schema_version: "secwatch.filing_event.v1"
accession: "0001831283-22-000037"
form_type: "8-K"
ticker: "LIANY"
cik: "0001831283"
company_name: "LianBio"
filed_at: "2022-05-12T23:59:59+00:00"
generated_at: "2026-06-25T19:14:55.798510+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# LianBio Q1 net loss narrows to $27.7M; cash $389.1M; mavacamten FDA approval

## Summary
- Net loss of $27.7M vs $61.6M in Q1 2021; R&D expenses fell to $12.3M from $53.4M.
- Cash balance $389.1M as of March 31, 2022; runway projected through mid-2024.
- Partner BMS received U.S. FDA approval for mavacamten in obstructive HCM in April 2022.
- Partner Tarsus reported positive Phase 3 Saturn-2 data for TP-03 in Demodex blepharitis; NDA planned H2 2022.
- Pfizer agreed to acquire development partner ReViral (sisunatovir); LianBio expects to start three Phase 3 trials in China by year-end.

## SEC filing metadata
- accession: 0001831283-22-000037
- form_type: 8-K
- ticker: LIANY
- cik: 0001831283
- company_name: LianBio
- filed_at: 2022-05-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831283/000183128322000037/0001831283-22-000037-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831283/000183128322000037/lian-20220512.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001831283-22-000037
- JSON: https://secwatch.observer/filing/0001831283-22-000037.json
- Plain text: https://secwatch.observer/filing/0001831283-22-000037.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.